Tuesday, 20 October 2026 Updated 14 min ago
The News Engine
Latest
Health United States

Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis

Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.

CNBC reports: Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.

This health story centres on the United States. Names and organisations mentioned in the coverage include CagriSema, GLP- and Wegovy.

Why it matters

Health stories are worth following because they can shape treatment options, guidance and how services are delivered. Readers should rely on medical professionals for personal advice.

Key details

Location
United States · Americas
Reported by
CNBC
First reported
Key names
CagriSema, GLP-, Wegovy
Section
Health

Sources

This is an independent summary. Read the full, original reporting from the publisher:

Read the full story at CNBC

Spotted an error? Request a correction · How this summary was produced

Related Stories